Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes

Leukemia

Volumn 17, Issue 8, 2003, Pages 1499-1507

  List, A ^a   Beran, M ^b   DiPersio, J ^c   Slack, J ^d   Vey, N ^e   Rosenfeld, C S ^f   Greenberg, P ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e INSTITUT PAOLI CALMETTES   (France)

^f TEXAS ONCOLOGY   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Cellular redox; Clinical trials; Myelodysplastic syndromes; Trisenox

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOTOXIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 6; RETINOIC ACID; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; LEUKEMIA; LONG QT SYNDROME; MAINTENANCE DRUG DOSE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; TORSADE DES POINTES; TREATMENT INDICATION; VERTIGO; CELL FUNCTION; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARSENICALS; CELL PHYSIOLOGY; CLINICAL TRIALS; HUMANS; MYELODYSPLASTIC SYNDROMES; OXIDES; TREATMENT OUTCOME;

EID: 0042528608     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403021     Document Type: Review

References (83)

1. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743-745.
2. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
3. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
4. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leukemia Res 1998; 22: 1123-1136.
5. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
6. Mundle SD, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999; 60: 36-47.
7. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201-207.
8. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275-4287.
9. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leukemia Res 1998; 22: 767-777.
10. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998; 103: 1075-1082.
11. Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
12. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
13. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-133.
14. L. Blood 2000; 95: 1014-1022.
15. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
16. Hong SH, Yang Z, Privalsky ML. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001; 21: 7172-7182.
17. Wang Z-G, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92: 1497-1504.
18. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776-780.
19. Zhu X-H, Shen Y-L, Jing Y-K, Cai X, Jia P-M, Huang Y et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-778.
20. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383-1391.
21. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
22. Huang X-J, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999; 16: 58-64.
23. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-1061.
24. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999; 27: 845-852.
25. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
26. Yang C-H, Kuo M-L, Chen J-C, Chen Y-C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81: 796-799.
27. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 2000; 275: 36062-36066.
28. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM et al. Phenylarsine oxide blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 1999; 94: 2844-2853.
29. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med 2002; 30(Suppl. 1): S74-S79.
30. Davison K, Mann KK, Miller Jr WH. Arsenic trioxide: mechanisms of action. Semin Hematol 2002; 39(Suppl. 1): 3-7.
31. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265-278.
32. Tennant GB, Walsh V, Truran LN, Edwards P, Mills KI, Burnett AK. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000; 111: 853-862.
33. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519.
34. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
35. Park J-W, Choi Y-J, Jang MA, Baek S-H, Lim JH, Passaniti T et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and Bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001; 286: 726-734.
36. Giles FJ. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt) 2002; 16(Suppl. 4): 23-29.
37. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033-6037.
38. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell Jr RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
39. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-458.
40. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia (letter). Blood 1997; 89: 3487-3488.
41. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3-5.
42. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58-62.
43. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
44. Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
45. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
46. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(Suppl. 2): 8-13.
47. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136-3143.
48. Soignet S, Bienvenu BJ, Vongphrachanh P, Garzone P, Cheung N-K, Calleja E et al. A clinical and pharmacologic study of arsenic trioxide (ATO). Clin Cancer Res (in press).
49. Brunnig R, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myelodysplastic syndromes: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001; pp 63-73.
50. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting. Airlie House, Warrenton, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
51. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
52. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82: 191-204.
53. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
54. Greenberg PL, Sanz GF, Sanz MA. Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum (Genova) 1999; 9: 17-31.
55. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
56. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-3076.
57. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 36-43.
58. Willemze R, van der LN, Zwierzina H, Suciu S, Solbu G, Gerhartz H et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 1992; 64: 173-180.
59. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71.
60. Kuter DJ. Future directions with platelet growth factors. Semin Hematol 2000; 37(Suppl. 4): 41-49.
61. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165-4172.
62. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455-462.
63. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364-3369.
64. Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A et al. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leukemia Lymphoma 1995; 19: 277-280.
65. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578-1584.
66. Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999; 78: 125-130.
67. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
68. Kornblith AB, Herndon II JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-2452.
69. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C et al. Patients with myelodysplastic syndromes benefit from palliative therapy with arnifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95: 1580-1587.
70. Maciejewski JP, Ristiano AM, Sloand EM, Wisch L, Geller N, Barrett JA et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002; 117: 119-126.
71. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14: 2-8.
72. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leukemia Res 2002; 26: 721-724.
73. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
74. Shimamoto T, Iguchi T, Ando K, Katagiri T, Tauchi T, Ito Y et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol 2001; 114: 358-361.
75. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leukemia Res 1998; 22(Suppl. 1): S17-S21.
76. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992; 65: 162-168.
77. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001; 114: 349-357.
78. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001; 92: 1999-2015.
79. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-2331.
80. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 2000; 85: 1002-1003.
81. Cheson BD, Bennett JM, Kantarjian H, PintoA, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
82. List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002; 7(Suppl. 1): 39-49.
83. Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12-25.